We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MKC:NYSEMcCormick & Company, Incorporated Analysis

Data as of 2026-06-12 - not real-time

$49.23

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

McCormick & Company (MKC) trades around $49.23, well above its DCF-derived fair value of $18.42, signaling a substantial overvaluation despite a low trailing P/E of 8.07 and a robust dividend yield of 3.9%. The company posted a 16.7% revenue growth year‑over‑year, healthy gross (38.2%) and operating margins (14.3%), and a solid free cash flow generation of $373 M, supporting its Buy analyst consensus and dividend sustainability. However, the price sits below its 20‑day (47.24) and 50‑day (49.24) SMAs and far above the 200‑day SMA (61.48), with the stock hovering near the identified support at $45.53 and facing resistance near $50.15, indicating a bearish technical backdrop.
The 30‑day volatility of ~26% and a negative beta (‑0.19) reflect heightened price swings yet low market correlation, while the consumer‑defensive sector provides a low‑risk backdrop. Increasing volume suggests renewed trader interest, but the combination of overvaluation, bearish trend direction, and elevated short‑term volatility warrants caution, making a near‑term sell stance prudent while the strong fundamentals justify a medium‑term buy outlook.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below short‑term moving averages and near support level
  • High short‑term volatility (~26%)
  • Significant overvaluation versus DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth (16.7%) and solid margins
  • Sustainable dividend with low payout ratio (30%)
  • Analyst consensus buy and attractive valuation multiples (P/E 8)

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Defensive consumer staple positioning with global brand portfolio
  • Consistent dividend aristocrat status and cash flow generation
  • Persistent valuation gap suggesting price may need correction

Key Metrics & Analysis

Financial Health

Revenue Growth16.70%
Profit Margin23.12%
P/E Ratio8.1
ROE25.35%
ROA4.88%
Debt/Equity65.16
P/B Ratio1.9
Op. Cash Flow$897.6M
Free Cash Flow$372.8M

Technical Analysis

TrendBearish
RSI56.2
Support$45.53
Resistance$50.15
MA 20$47.24
MA 50$49.24
MA 200$61.48
MACDBullish
VolumeIncreasing
Fear & Greed Index87.77

Valuation

Fair Value$18.42
Target Price$61.31
Upside/Downside24.53%
GradeOvervalued
TypeBlend
Dividend Yield3.90%

Risk Assessment

Beta-0.19
Volatility25.89%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.